ORGANIZATION

• JPMA Reprimands Meiji Pharma over Kobayashi Kako Issue
  July 16, 2021

• Hiroyuki Kawabata Joins PhRMA as Sr. Assistant Japan Representative
  July 16, 2021

• Downloads of FPMAJ’s E-Labeling App on Track to Target 50,000 as Legal Enforcement Approaches
  July 14, 2021

• Japan Patient Advocates Want Drugs for Later-Stage Alzheimer’s
  July 13, 2021

• New Trade Group for Established Drugs to Launch in Japan
  July 13, 2021

• FIRM Calls for Separate Pricing System for Regenerative Medicine Products: Chair
  July 13, 2021

• JMA Frets Pricey Dementia Meds, to Explore Ways to Keep Universal Coverage
  July 9, 2021

• High-Priced Drugs Should Be Discussed Carefully Based on Characteristics of Diseases and Treatments: JMA Exec
  July 1, 2021

• More than 80% of Pharmacists Feel Impact of Generic Supply Delays on Business: Survey
  June 23, 2021

• Patient Group Wants More R&D Spending on Pancreatic Cancer
  June 15, 2021

• Saitama-Based Hospital Group Introduces Formulary in 18 Therapeutic Areas, Aims to Spread Know-How in Region
  June 15, 2021

• FPMAJ Urges Caution with Market Expansion Re-Pricing, Says Add’l Indications Now Seen as Price Cut Risk
  June 14, 2021

• FPMAJ Drug Price Report Rebuts Issues Raised over Cost-Plus Method, PMP and More
  June 14, 2021

• PhRMA Posts Its Position on Japan CEA Scheme on Website
  June 11, 2021

• Eisai’s Akana Re-Elected as FPMAJ’s Drug Pricing Chief
  June 11, 2021

• Terumo’s Mimura Elected New Medical Devices Chief; Reimbursement Debate Ahead for SaMD
  June 9, 2021

• Experts Eye Macroeconomic Indexing of Drug Costs to Keep Innovation Afloat: INES Proposal
  May 31, 2021

• Ken Suzuki Returns to JPWA Reins after 2 Years
  May 28, 2021

• JPMA Positive on Use of Clinical Research Data in Submissions, but Wary of Funding Database
  May 26, 2021

• Ken Suzuki Likely to Come Back as JPWA Chief after 2 Years
  May 25, 2021

ページ

• « 先頭
• ‹ Prev
• …
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31
• 32
• …
• Next ›
• 最終 »